Entera Bio (NASDAQ:ENTX) Trading Down 2.1% – Here’s What Happened

by · The Cerbat Gem

Entera Bio Ltd. (NASDAQ:ENTX – Get Free Report)’s stock price fell 2.1% on Wednesday . The stock traded as low as $2.70 and last traded at $2.81. Approximately 308,461 shares traded hands during mid-day trading, a decline of 94% from the average session volume of 4,870,486 shares. The stock had previously closed at $2.87.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. HC Wainwright reaffirmed a “buy” rating on shares of Entera Bio in a report on Wednesday, June 24th. Weiss Ratings reissued a “sell (d-)” rating on shares of Entera Bio in a report on Friday, July 17th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $9.00.

Read Our Latest Stock Analysis on ENTX

Entera Bio Stock Down 2.1%

The stock has a market cap of $138.50 million, a PE ratio of -10.41 and a beta of 1.38. The business has a 50 day moving average price of $1.78 and a 200 day moving average price of $1.47.

Entera Bio (NASDAQ:ENTX – Get Free Report) last posted its earnings results on Friday, May 8th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.01. On average, research analysts predict that Entera Bio Ltd. will post -0.34 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Entera Bio

Hedge funds and other institutional investors have recently made changes to their positions in the company. Schonfeld Strategic Advisors LLC increased its holdings in shares of Entera Bio by 5.2% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 596,585 shares of the company’s stock valued at $1,157,000 after purchasing an additional 29,629 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in Entera Bio by 22.2% during the fourth quarter. Renaissance Technologies LLC now owns 108,001 shares of the company’s stock worth $210,000 after buying an additional 19,601 shares in the last quarter. Jane Street Group LLC grew its position in Entera Bio by 142.6% during the fourth quarter. Jane Street Group LLC now owns 74,064 shares of the company’s stock valued at $144,000 after buying an additional 43,536 shares during the period. HighTower Advisors LLC grew its position in Entera Bio by 137.8% during the fourth quarter. HighTower Advisors LLC now owns 43,140 shares of the company’s stock valued at $84,000 after buying an additional 25,000 shares during the period. Finally, Citadel Advisors LLC grew its position in Entera Bio by 243.0% during the third quarter. Citadel Advisors LLC now owns 39,978 shares of the company’s stock valued at $77,000 after buying an additional 28,322 shares during the period. Institutional investors and hedge funds own 14.11% of the company’s stock.

About Entera Bio

(Get Free Report)

Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.

Further Reading